Mitsubishi Tanabe Pharma America, Inc. (MTPA) is committed to providing significant scientific advances designed to provide important treatments to those facing serious and life-threatening diseases.
MTPA is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). MTPC is one of the world’s oldest medicines companies, with over 300 years of experience advancing innovative treatments.
In 2009, MTPC opened its first U.S. headquarters with a focus on developing and commercializing new compounds for the U.S. market.
MTPA officially launched in 2016 with the ambitious goal of developing therapies for some of the most difficult-to-treat diseases, including amyotrophic lateral sclerosis (ALS).
JAPAN TO JERSEY CITY, N.J.
MTPA has built an accomplished team in Jersey City, N.J., an urban center that is in the midst of its own rapid growth. MTPC has invested significantly in developing its U.S. operations. Since 2016, the number of U.S. employees has grown from approximately 5 to over 50, and we are continuing to expand our team in the year ahead.
The growing team pairs its global expertise in research and development with accomplished veterans of the U.S. life science industry and applies its deep experience and pioneering spirit to find the best way to bring new treatments to market.
The Corporate Symbol of Mitsubishi Tanabe Pharma America is a registered trademark of Mitsubishi Tanabe Pharma Corporation.